Trianni licenses humanized model platform to MacroGenics for oncology research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/sidsnapper)
(Image: Getty/sidsnapper)

Related tags: models, Model organism, Mouse models, Research and development, R&D, Immune response, License

Trianni to provide MacroGenics with humanized mouse model platform for its mAb therapeutics research.

MacroGenics has licensed The Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies (mAb). The agreement with Trianni will support MacroGenics’ discovery programs for mAb therapeutics used in oncology.

Ezio Bonvini, chief scientific officer of MacroGenics, said in a press release, that the company can use the mouse for its molecules that are based on its Fc optimization and multi-specific DART and TRIDENT platforms. Applying antibodies into these molecules MacroGenics can accelerate its candidate development processes.

Trianni’s platform combines human antibody repertoire with wild-type mouse immune responses to target antigens, according to the company.

Trianni did not respond to a request for comment.

In October of 2017, Juno Therapeutics also signed a licensing agreement with Trianni for its mAb platform. Juno used the mouse model to identify full-human binders for conversion to chimeric antigen receptors as part of the company’s engineered T cell programs.

Juno stated at the time that it was to use the program to establish “next-generation CAR-T cells.”

Humanized mouse model systems are not new, but technology is emerging that could improve their use. Recently, scientists at CytoReason developed a mouse to human​ model. The model is a machine-learning platform for human immune system cell-level simulation. 

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars